Cardiovascular disease continues to be the leading cause of death worldwide. To save lives, constantly improving diagnostic ...

For prostate biopsy planning, multiparametric MRI has relatively low specificity particularly for PI-RADS 3 and PI-RADS 4 ...

Up to 105 Japanese men will be enrolled at 11 sites, with data aimed at supporting a future marketing authorisation submission.

Siemens Healthineers announced today that it received FDA clearance for its Biograph One second-generation PET/MR scanner.

Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

As Telix Pharmaceuticals turns the page on 2025, its annus horribilis, analysts remain optimistic around a potential ...

Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, ...

By recognizing patterns in test results, AI can identify patients at risk of cancer, diabetes complications, heart disease ...

Introduction: The BIOPSTAGE trial investigates the added diagnostic value of combining prostate-specific membrane antigen positron emission tomography (PSMA PET) with multiparametric MRI (mpMRI) for ...

Abstract: Prostate cancer is still a major health problem for men worldwide. This problem emphasizes the importance of accurate diagnosis, early detection and treatment planning. Imaging techniques ...

Mon Health Cancer Center now offers PLUVICTO, a targeted radiation therapy for men with PSMA-positive metastatic castration-resistant prostate cancer, often after other treatments like chemotherapy.